semaglutide eye problems Rybelsus Vision Loss Lawsuit [2026 Update] Semaglutide Linked to Increased Risk

Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss

The idea of regulating glucose levels through DPP-4 inhibition was initially conceived 25 years ago, paving the way for the development of different DPP-4 inhibitors and their widespread clinical utilization [38]

NG69 Recommendations chapter

J Am Acad Dermatol 89:758763

Slowed colonic transit (not just gastric emptying) is a GLP-1 class effect